Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

6.0K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
6.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Virome-wide ubiquitin ligase discovery reveals diverse mechanisms of immune evasion.

Science (New York, N.Y.)·2026
Same author

Degron-independent recruitment of KAT2A expands the target space of CRBN molecular glues.

Science (New York, N.Y.)·2026
Same author

A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II Inhibition.

Journal of the American Chemical Society·2026
Same author

Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response.

Nature communications·2026
Same author

Efficient prime editing in vivo and in vitro using lipid nanoparticles.

Nature nanotechnology·2026
Same author

Distinct Proteasomal Pathways Drive Oncogenic PPM1D Activation.

bioRxiv : the preprint server for biology·2026

相关实验视频

Updated: Jul 8, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.7K

针对蛋白质溶解的嵌合体具有减少的非目标.

Tuan M Nguyen1,2,3, Vedagopuram Sreekanth1,2,3, Arghya Deb1,2

  • 1Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Nature chemistry
|December 18, 2023
PubMed
概括

使用波马利多米德的蛋白质溶解向金像体 (PROTACs) 可以降解意外的指蛋白. 修改波马利多米德的方法

更多相关视频

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.4K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K

相关实验视频

Last Updated: Jul 8, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.7K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.4K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.2K

科学领域:

  • 生物化学 生化学
  • 分子生物学分子生物学
  • 药物发现 药物发现 药物发现

背景情况:

  • 向蛋白质分解的嵌合体 (PROTACs) 利用E3链酶进行向蛋白质降解.
  • 利多米德是PROTAC中常见的E3酶招募剂,它表现出指 (ZF) 蛋白的非目标降解.
  • 这种非目标效应限制了基于波马利多米德的PROTACs的治疗潜力.

研究的目的:

  • 为了调查和减轻由利多米德基PROTACs诱导的非目标指蛋白降解.
  • 建立PROTAC设计原则,尽量减少意外的蛋白质降解.
  • 开发更高效率和特异性的改进的PROTAC.

主要方法:

  • 开发一个高吞吐量平台,用于询问非目标降解.
  • 合成和选的图书馆的pomalidomide类似物与修改在phthalimide环.
  • 评估对ZF蛋白质降解的结,硬质和疏水效应.
  • 使用目标参与测试和蛋白质组学进行验证.
  • 设计和测试对形淋巴瘤激酶 (ALK) 在基蛋白向的PROTACs.

主要成果:

  • 现有的基于波马利多米德的PROTAC被证实会降解多个ZF蛋白.
  • 在甲胺环的C5位置的修改有效地减少了非目标ZF蛋白降解.
  • 结构-活动关系研究阐明了影响非目标效应的关键因素.
  • 新型向ALK的PROTACs表现出强度增加,并且显著减少了目标外降解.

结论:

  • 战略性修改波马利多米德类似物可以最大限度地减少非目标ZF蛋白降解.
  • 这些发现为开发更安全,更有效的PROTAC提供了关键的设计规则.
  • 开发的PROTACs代表了针对性癌症治疗的有希望的进步,以ALK抑制为例.